Oncology Leads Personalized Medicine

Study finds that almost 75% of cancer drug candidates rely on biomarker data.

The opportunity to more precisely target and to personalize medical treatments based on biomarker data has attracted growing interest from biopharmaceutical companies. A recent study by the Tufts Center for the Study of Drug

Development (Tufts CSDD) finds that oncology dominates personalized medicine product development in part because cancer-related illnesses are extremely complex and they receive the highest level of R&D activity. Companies involved in developing personalized medicines report that across all phases, 73% of oncology drugs now rely on biomarker data. This compares with 42% of compounds in all indications.

- Tufts CSDD

Articles in this issue

over 10 years ago

Article

FDA Seeks Resources to Support New Research Initiatives

over 10 years ago

Article

Safety Considerations for Follow-On Non-Biologic Complex Drugs

over 10 years ago

Article

Putting the EMA House in Order

over 10 years ago

Article

Experts Call for Urgent Action on Antibiotics Research

over 10 years ago

Article

Characterizing the Real Cost of Site Regulatory Compliance

over 10 years ago

Article

Using 505(b)(2) to Solve Shortfall from Generic Cliff

over 10 years ago

Article

Lifecycle Modeling and Simulation in Clinical Trials

over 10 years ago

Article

over 10 years ago

Article

Managing Portfolios for Economic and Clinical Value

over 10 years ago

Article

Applied Clinical Trials Digital Edition - June/July 2015

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!